GenMont Biotech Inc - Asset Resilience Ratio

Latest as of December 2025: 19.76%

GenMont Biotech Inc (3164) has an Asset Resilience Ratio of 19.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GenMont Biotech Inc (3164) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$329.06 Million

≈ $10.37 Million USD Cash + Short-term Investments

Total Assets

NT$1.67 Billion

≈ $52.46 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2025)

This chart shows how GenMont Biotech Inc's Asset Resilience Ratio has changed over time. See GenMont Biotech Inc net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down GenMont Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of GenMont Biotech Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$329.06 Million	19.76%
Total Liquid Assets	NT$329.06 Million	19.76%

Asset Resilience Insights

Good Liquidity Position: GenMont Biotech Inc maintains a healthy 19.76% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

GenMont Biotech Inc Industry Peers by Asset Resilience Ratio

Compare GenMont Biotech Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for GenMont Biotech Inc (2003–2025)

The table below shows the annual Asset Resilience Ratio data for GenMont Biotech Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	19.76%	NT$329.06 Million ≈ $10.37 Million	NT$1.67 Billion ≈ $52.46 Million	+5.24pp
2024-12-31	14.52%	NT$248.13 Million ≈ $7.82 Million	NT$1.71 Billion ≈ $53.83 Million	-1.97pp
2023-12-31	16.50%	NT$272.71 Million ≈ $8.59 Million	NT$1.65 Billion ≈ $52.08 Million	+0.74pp
2022-12-31	15.76%	NT$267.26 Million ≈ $8.42 Million	NT$1.70 Billion ≈ $53.43 Million	+0.93pp
2021-12-31	14.83%	NT$251.78 Million ≈ $7.93 Million	NT$1.70 Billion ≈ $53.50 Million	+3.03pp
2020-12-31	11.80%	NT$190.28 Million ≈ $5.99 Million	NT$1.61 Billion ≈ $50.81 Million	-9.51pp
2019-12-31	21.31%	NT$334.80 Million ≈ $10.55 Million	NT$1.57 Billion ≈ $49.50 Million	-21.00pp
2018-12-31	42.31%	NT$701.60 Million ≈ $22.10 Million	NT$1.66 Billion ≈ $52.25 Million	+28.86pp
2017-12-31	13.44%	NT$201.69 Million ≈ $6.35 Million	NT$1.50 Billion ≈ $47.26 Million	+4.45pp
2016-12-31	8.99%	NT$126.24 Million ≈ $3.98 Million	NT$1.40 Billion ≈ $44.23 Million	-2.69pp
2015-12-31	11.68%	NT$190.89 Million ≈ $6.01 Million	NT$1.63 Billion ≈ $51.47 Million	+12.49pp
2014-12-31	-0.81%	NT$-14.05 Million ≈ $-442.56K	NT$1.74 Billion ≈ $54.88 Million	-44.92pp
2013-12-31	44.11%	NT$606.01 Million ≈ $19.09 Million	NT$1.37 Billion ≈ $43.28 Million	-4.03pp
2012-12-31	48.15%	NT$687.66 Million ≈ $21.66 Million	NT$1.43 Billion ≈ $45.00 Million	-11.31pp
2011-12-31	59.46%	NT$887.58 Million ≈ $27.96 Million	NT$1.49 Billion ≈ $47.03 Million	+71.86pp
2010-12-31	-12.40%	NT$-169.36 Million ≈ $-5.34 Million	NT$1.37 Billion ≈ $43.02 Million	-61.81pp
2007-12-31	49.41%	NT$282.47 Million ≈ $8.90 Million	NT$571.68 Million ≈ $18.01 Million	+48.57pp
2006-12-31	0.84%	NT$4.39 Million ≈ $138.18K	NT$520.93 Million ≈ $16.41 Million	-0.48pp
2005-12-31	1.32%	NT$4.15 Million ≈ $130.87K	NT$313.55 Million ≈ $9.88 Million	-25.08pp
2004-12-31	26.41%	NT$81.62 Million ≈ $2.57 Million	NT$309.07 Million ≈ $9.74 Million	-0.65pp
2003-12-31	27.06%	NT$69.88 Million ≈ $2.20 Million	NT$258.26 Million ≈ $8.14 Million	--

pp = percentage points

About GenMont Biotech Inc

TW:3164 Taiwan Biotechnology

Market Cap

$44.44 Million

NT$1.41 Billion TWD

Market Cap Rank

#22421 Global

#1391 in Taiwan

Share Price

NT$16.40

Change (1 day)

+0.00%

52-Week Range

NT$16.25 - NT$21.35

All Time High

NT$30.54